Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

r-Sm14 - pRSETA efficacy in experimental animals.

C R Ramos1, M M Vilar, A L Nascimento

  • 1Centro de Biotecnologia, Instituto Butantan, São Paulo, SP, Brasil.

Memorias Do Instituto Oswaldo Cruz
|October 5, 2001
PubMed
Summary

New expression systems for Sm14 antigen, a potential vaccine for schistosomiasis, offer improved yield and purification. These systems provide protective activity comparable to previous methods, aiding large-scale production for clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New IMPACT Guideline to help doctors on rational prescription of antimicrobials.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

Emotional Welfare and Its Relationship with Social Interactions and Physical Conditions of Finishing Pigs in Lairage at the Slaughterhouse.

Animals : an open access journal from MDPI·2025
Same author

Analysis of brazilian paintings of the 20th century: Suspects and authentics through in situ and Non-Invasive techniques.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2023
Same author

Prospective international validation of the predisposition, infection, response and organ dysfunction (PIRO) clinical staging system among intensive care and general ward patients.

Annals of intensive care·2021
Same author

Acute flaccid paralysis associated with enterovirus D68 infection: a case report.

Hong Kong medical journal = Xianggang yi xue za zhi·2021
Same author

Improving the preparedness against an oil spill: Evaluation of the influence of environmental parameters on the operability of unmanned vehicles.

Marine pollution bulletin·2021

Area of Science:

  • Parasitology
  • Vaccinology
  • Biotechnology

Background:

  • Recombinant Sm14 (rSm14) produced in Escherichia coli using the pGEMEX system showed high protective activity against Schistosoma mansoni infections.
  • This rSm14 was endorsed by the World Health Organization for clinical trials.
  • The pGEMEX system has limitations for large-scale production due to time consumption and low yield.

Purpose of the Study:

  • To evaluate alternative Escherichia coli expression systems for Sm14 production suitable for scale-up.
  • To develop a more efficient method for producing Sm14 for potential large-scale vaccine manufacturing.

Main Methods:

  • Expressed two different 6XHis-tagged Sm14 fusion proteins in E. coli using T7 promoter-based plasmids.
  • Purified the recombinant proteins using Ni+2-charged resin chromatography.

Related Experiment Videos

  • Validated protein identity using Western-Blot with anti-Sm14 antibodies and anti-S. mansoni antiserum.
  • Assessed protective activity in animal models against S. mansoni cercariae challenge.

    • Main Results:

    • Successfully expressed and purified two 6XHis-tagged Sm14 fusion proteins (18 and 16 kDa).
    • The expressed proteins were recognized by specific antibodies, confirming their identity.
    • Both new recombinant Sm14 proteins demonstrated protective activity against S. mansoni infection, equivalent to the pGEMEX-derived rSm14.
    • The 6XHis-tag facilitated rapid purification, indicating suitability for downstream processing.

    Conclusions:

    • Alternative E. coli expression systems with 6XHis-tagging are effective for producing Sm14 antigen.
    • These systems offer advantages in purification efficiency and scalability compared to the pGEMEX system.
    • The findings support the development of Sm14 as a vaccine candidate for schistosomiasis control through improved manufacturing processes.